Ubs Group Ag Caladrius Biosciences, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$0.41 - $0.74 $10,093 - $18,218
24,619 Added 639.79%
28,467 $15,000
Q1 2022

May 16, 2022
SELL
$0.63 - $1.03 $34,139 - $55,814
-54,189 Reduced 93.37%
3,848 $3,000
Q4 2021

Feb 14, 2022
BUY
$0.83 - $1.22 $38,548 - $56,661
46,444 Added 400.62%
58,037 $49,000
Q3 2021

Nov 15, 2021
BUY
$1.15 - $1.57 $13,320 - $18,185
11,583 Added 115830.0%
11,593 $14,000
Q1 2021

May 12, 2021
SELL
$1.44 - $2.89 $9,331 - $18,727
-6,480 Reduced 99.85%
10 $0
Q4 2020

Feb 11, 2021
BUY
$1.39 - $1.87 $9,007 - $12,117
6,480 Added 64800.0%
6,490 $9,000
Q2 2020

Jul 31, 2020
SELL
$1.66 - $2.38 $7,567 - $10,850
-4,559 Reduced 99.78%
10 $0
Q1 2020

May 01, 2020
BUY
$1.21 - $3.47 $2,514 - $7,210
2,078 Added 83.42%
4,569 $8,000
Q4 2019

Feb 14, 2020
BUY
$2.02 - $2.85 $5,011 - $7,070
2,481 Added 24810.0%
2,491 $6,000
Q2 2019

Aug 14, 2019
SELL
$2.25 - $3.6 $9,128 - $14,605
-4,057 Reduced 99.75%
10 $0
Q1 2019

May 14, 2019
BUY
$3.48 - $5.32 $4,729 - $7,229
1,359 Added 50.18%
4,067 $15,000
Q4 2018

Feb 14, 2019
BUY
$3.49 - $5.77 $9,416 - $15,567
2,698 Added 26980.0%
2,708 $10,000
Q3 2018

Nov 14, 2018
SELL
$4.85 - $6.5 $2,648 - $3,549
-546 Reduced 98.2%
10 $0
Q2 2018

Aug 14, 2018
SELL
$3.8 - $8.64 $3,560 - $8,095
-937 Reduced 62.76%
556 $4,000
Q1 2018

May 15, 2018
SELL
$3.7 - $6.09 $62 - $103
-17 Reduced 1.13%
1,493 $9,000
Q4 2017

Feb 14, 2018
BUY
$2.66 - $3.71 $2,021 - $2,819
760 Added 101.33%
1,510 $5,000
Q3 2017

Nov 14, 2017
SELL
$3.58 - $4.34 $6,225 - $7,547
-1,739 Reduced 69.87%
750 $3,000
Q2 2017

Aug 14, 2017
SELL
N/A
-792 Reduced 24.14%
2,489 $11,000
Q1 2017

Nov 14, 2017
BUY
N/A
3,281
3,281 $17,000

About CALADRIUS BIOSCIENCES, INC.

CLBS Quotes by TradingView
  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email